Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T, Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U, Zeuzem S. Berg T, et al. Among authors: buggisch p. Gastroenterology. 2006 Apr;130(4):1086-97. doi: 10.1053/j.gastro.2006.02.015. Gastroenterology. 2006. PMID: 16618403 Clinical Trial.
Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.
Halangk J, Sarrazin C, Neumann K, Puhl G, Mueller T, Teuber G, Klinker H, Hinrichsen H, Buggisch P, Landt O, Weich V, Bergk A, Wiedenmann B, Neuhaus P, Berg T, Witt H. Halangk J, et al. Among authors: buggisch p. J Hepatol. 2008 Sep;49(3):339-45. doi: 10.1016/j.jhep.2008.05.021. Epub 2008 Jun 23. J Hepatol. 2008. PMID: 18644651
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.
Deterding K, Wiegand J, Grüner N, Hahn A, Jäckel E, Jung MC, Buggisch P, Galle P, Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H. Deterding K, et al. Among authors: buggisch p. Z Gastroenterol. 2009 Jun;47(6):531-40. doi: 10.1055/s-0028-1109149. Epub 2009 Jun 16. Z Gastroenterol. 2009. PMID: 19533544
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG, Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T. van Bömmel F, et al. Among authors: buggisch p. Hepatology. 2010 Jan;51(1):73-80. doi: 10.1002/hep.23246. Hepatology. 2010. PMID: 19998272
The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.
Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schürmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Gölz J, Staszewski S, Rockstroh JK. Vogel M, et al. Among authors: buggisch p. Eur J Med Res. 2010 Mar 30;15(3):102-11. doi: 10.1186/2047-783x-15-3-102. Eur J Med Res. 2010. PMID: 20452894 Free PMC article. Clinical Trial.
147 results